IPIRA Startups

IPIRA Startups

Vitapath Genetics Inc.

Brief Description

VitaPath develops and performs genomic-based tests to determine an individual's need for targeted therapy in certain medical conditions treatable with vitamins. Using our platform, we are leading the exploration of the Vitanome, the subset of information that lies within our genomes that plays a critical role in how we metabolize vitamins, and the commercialization of specific assays that test vitamin-remediable genetic variants. VitaPath's genetic tests are performed by highly skilled professionals in our CLIA-certified, CAP-accredited Clinical Laboratory....

Videnda, Inc.

Brief Description

Cellular Neural Network universal machine and super computer, nonlinear networks.

Inventors

Leon O. Chua, Tamas Roska, Frank Werblin, Lin Yang

Timeline 2000. Company founded.

Ventria Biosciences (formerly known as Applied Phytologics Inc.)

Brief Description

Ventria Bioscience is a privately held biopharmaceutical company with a product pipeline enabled by ExpressTec. ExpressTec is a patented, plant-based recombinant protein manufacturing technology that delivers a ten-fold higher recombinant protein yield than other plant-based systems. Ventria Bioscience's platform technology delivers meaningful and sustainable economic advantages by enabling new product opportunities that were not previously available. It can be used to develop new biotherapeutics, novel vaccines, reagents for biomanufacturing, and industrial and biofuel...

Vicinitas Therapeutics

Brief Description

Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. The company spun out of technology that was developed through an academic-industry collaboration between UC Berkeley researchers and Novartis Institutes for BioMedical Research.

Inventors

Dan Nomura...

Vedere Bio II

Brief Description

Vedere Bio II is pioneering beyond traditional gene therapy to not just slow vision loss from inherited retinal degenerations (IRDs) or dry age-related macular degeneration (dry AMD) with geographic atrophy (GA), but actually restore it.

Inventors

Matthew Banghart, Michael Hayden Berry, Katherine Borges, Johannes Broichhagen, John Flannery, Doris Fortin, Benjamin Gaub, Scott Franklin Geller, Pablo Gorostiza, Karen Isabelle Guerin, Amy Holt, Ehud Isacoff, Richard Kramer, Joshua Levitz, Katharine Munckton, Autoosa Salari, Dirk Trauner, Meike Visel, Matthew Volgraf...

Vedere

Brief Description

Vedere Bio, Inc. was developing gene therapy products to restore functional vision to patients who have suffered vision loss from inherited retinal degenerations, as well as other causes of both genetic and non-genetic vision loss. Vedere aimed to restore lost vision regardless of a patient's underlying genetics or their stage of disease.

Vedere was acquired by Novartis in 2020.

Inventors

Ehud Isaacoff, John Flannery, Amy Holt, Autoosa Salari, Benjamin Gaub, Dirk Trauner, Doris Fortin, Johannes Broichhagen, Joshua Levitz, Karen Isabelle Guerin, Katharine...

Varada Agriculture

Brief Description

Varada Agriculture is transforming pest management to reduce crop loss with proprietary RNA interference (RNAi) technology. The company's biodegradable products are safer for workers and consumers, while also minimizing residue impact on the environment. The company's RNAi technology uses inhibitory RNA molecules uniquely designed to work on a target organism without impacting beneficial organisms in nature. This method follows the Integrated Pest Management Plan principles, which recommend highly targeted pest control.

Founder and CEO Jyoti Taneja was a postdoc...

Valitor Inc.

Brief Description

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity, and bioactivity. The company's technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. The lead product will be used to improve the treatment of diseases in ophthalmology. The company also has development pipelines for oncology and orthopedics products.

The company was incubated at Berkeley Skydeck, UC Berkeley's...

UrbanScan

Brief Description

UrbanScan developed technologies for producing 3D virtual models with LiDar and video camera data. The technology was originally developed in the lab of Professor of Electrical Engineering and Computer Sciences Professor Avideh Zakhor, who co-founded UrbanScan in 2005.

Google acquired the UrbanScan technology in 2007, and used the software for web-based 3D reconstruction of urban landscapes as the basis for Google Earth.

Inventors

John Flynn, Christian Frueh, Siddharth Jain, Russell Sammon, Avideh Zakhor

Timeline 2005...

Tularik Inc.

Brief Description

Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity.

Tularik was co-founded in 1991 by UC Berkeley Professor Robert Tjian. Amgen acquired Tularik for $1.3 billion in 2004.

Inventors

Lucio Comai, Brian D. Dynlact, Timothy...